ITGB3 and myeloid sarcoma: This previously unrecognized PTN–ITGB3 axis could represent a novel mechanistic node in MS pathogenesis that warrants further functional validation and exploration as a potential therapeutic target to modulate CNS immune cell trafficking and disease heterogeneity.